company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13621000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,154000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13775000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13775000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6716000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,2313000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4855000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13884000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-109000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,178000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,217000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,395000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,286000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,475000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-189000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-189000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-189000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41848000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41848000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 13:47:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20754000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,154000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20908000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20908000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6409000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,2602000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6262000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15273000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5635000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,114000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3384000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3270000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2365000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,418000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1947000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1947000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1947000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41849000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.05
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41849000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.05
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,38900000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 12:45:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.05
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,12020000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,154000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,12174000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12174000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9697000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,2418000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9220000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21335000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9161000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,611000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,70000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-135000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-676000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9837000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2928000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6909000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6909000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6909000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41851000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41851000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,40600000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:20:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13846000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,154000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14000000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14000000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11694000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,2028000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7893000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21615000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7615000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,614000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,55000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3122000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3681000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11296000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2277000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9019000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9019000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9019000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41864000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.22
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41864000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.22
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41000000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 15:50:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.22
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14217000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,155000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14372000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14372000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7926000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,2243000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8725000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18894000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4522000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,619000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,35000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1224000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,640000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3882000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,196000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4078000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4078000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4078000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41877000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41877000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,40800000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 15:42:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,-40700000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,154000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,-40546000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-40546000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11953000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,2094000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7659000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,17689000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-11100000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-61844000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3609000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,611000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,89000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,14000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-508000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3101000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,401000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,17306000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,20006000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,-17306000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2700000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,-17306000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,20006000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41839000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.08
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41839000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.08
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.49
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14279000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,167000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14446000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14446000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7327000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,4089000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3352000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14768000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-322000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,592000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,20000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1274000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,702000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,380000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2308000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1928000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1928000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1928000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41702000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.05
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41702000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.05
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,38600000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 16:20:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.05
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,16556000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,127000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,16683000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16683000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8015000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,6107000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5235000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19357000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2674000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,592000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,30000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-555000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1117000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3791000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2972000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-819000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-819000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-819000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41710000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.02
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41710000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41000000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 16:15:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.02
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15357000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,139000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15496000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15496000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7256000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,4278000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5615000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17149000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1653000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,596000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,68000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,8000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-520000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2173000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3776000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5949000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5949000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5949000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41678000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41678000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42500000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 11:34:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,34662000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,200000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,34862000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3030000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3030000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,31832000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7559000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,4217000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7090000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18866000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,12966000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,566000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,61000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,875000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,370000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,13336000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-196000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,13532000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,13532000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,13532000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41660000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.33
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41785000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.33
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,40300000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.33
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,16755000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,164000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,16919000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1282000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1282000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15637000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7227000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,5389000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5629000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18245000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2608000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,495000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,19000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1081000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,605000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2003000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1142000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3145000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3145000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3145000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41461000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.08
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41461000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.08
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39300000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:51:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.08
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,26860000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,163000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,27023000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1908000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1908000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,25115000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5968000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,4553000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4425000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14946000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,10169000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,493000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,23000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,744000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,274000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,10443000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4324000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6119000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6119000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6119000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41604000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.15
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42868000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.14
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,40800000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 16:15:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.15
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21000000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,163000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21163000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6267000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6267000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14896000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5440000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,6026000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4474000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15940000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1044000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,461000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,20000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,183000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-258000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1302000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2825000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1523000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1523000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1523000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41863000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.04
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42787000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.04
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,152300000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 07:30:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.01
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24325000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,164000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24489000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2945000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2945000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21544000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6778000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,5091000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6996000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18865000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2679000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,445000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,62000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1509000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1126000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3805000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1287000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2518000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2518000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2518000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41716000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.06
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42544000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.06
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41300000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.09
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21959000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,202000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22161000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3517000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3517000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18644000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7257000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,3647000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5135000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16039000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2605000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,400000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,57000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-323000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-666000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1939000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1264000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,675000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,675000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,675000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43401000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.02
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,44264000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.02
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33800000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 15:14:46+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.02
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23854000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,215000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24069000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3796000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3796000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20273000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8197000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,4013000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4252000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16462000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3811000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,392000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,23000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-53000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-422000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3389000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1779000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1610000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1610000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1610000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43640000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.04
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43640000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.04
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,40300000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 14:05:52+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.04
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,31261000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,202000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,31463000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4974000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4974000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,26489000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8117000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,3801000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5297000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,5631000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22846000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3643000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,384000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,26000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,519000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,161000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3804000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2324000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1480000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1480000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1480000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43796000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.03
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43796000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.03
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,49300000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:04:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.03
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,29235000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,245000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,29480000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6110000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6110000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,23370000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6283000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,640000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6793000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13716000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,9654000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,276000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,40000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-203000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-439000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,9215000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2807000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6408000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6408000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6408000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,44366000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.14
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45912000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.14
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45800000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 18:15:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.14
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,33056000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,1828000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,34884000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7260000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7260000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,27624000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8328000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,592000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7124000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16044000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,11580000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,265000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,53000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2063000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1851000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,13431000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3855000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,9576000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,9576000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,9576000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,44627000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.21
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,46199000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.21
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45600000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q2,2015-04-01,2015-06-30,2016-08-03 16:06:52+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.21
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,33064000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,384000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,33448000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5286000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5286000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,28162000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7752000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,385000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8368000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16505000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,11657000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,243000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,62000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,87000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-94000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,11563000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4327000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,7236000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,7236000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,7236000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,44731000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.16
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,46309000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.16
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45200000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q3,2015-07-01,2015-09-30,2015-11-04 16:04:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.16
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,55258000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,110000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,55368000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,18075000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,18075000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,37293000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13154000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,1225000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11346000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25725000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,11568000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6070000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,26000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3942000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2102000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,9466000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-685000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,10151000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,10151000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,10151000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,44150000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.25
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45680000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.22
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43900000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.25
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,46741000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,467000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,47208000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,23338000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,23338000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,23870000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8927000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,775000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14671000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24373000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-503000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6270000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,25000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-347000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6592000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7095000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-3038000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4057000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4057000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4057000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42539000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42539000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,40600000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 17:13:43+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,50493000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,1458000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,51951000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,20354000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,20354000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,31597000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12423000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,623000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10933000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23979000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,7618000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5972000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,10000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2539000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8501000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-883000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-51000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-832000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-832000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-832000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41600000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.02
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41600000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42759000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 06:36:17+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.02
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,55497000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,2376000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,57873000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,15586000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,15586000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,42287000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11061000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,696000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9976000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,7286000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29019000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,13268000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5899000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,31000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,8102000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2234000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,15502000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7410000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,8092000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,8092000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,8092000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42813000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.19
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43443000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.19
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42600000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 06:35:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.19
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,71384000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,1640000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,73024000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,16725000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,16725000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,56299000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11387000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,384000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11035000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22806000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,33493000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,19667000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,6000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-6981000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-26642000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6851000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-8433000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,15284000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,15284000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,15284000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42791000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.36
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43749000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.35
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43000000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.36
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,56037000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,246000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,56283000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,16883000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,16883000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,39400000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17691000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,516000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10333000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,28540000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,10860000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2890000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,28000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,211000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2651000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,8209000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3585000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4624000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4624000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4624000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43442000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.11
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,62107000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.1
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42000000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 17:13:43+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.11
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,59850000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,46000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,59896000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,17035000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,17035000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,42861000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11583000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,1411000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,205702000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,218696000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-175835000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2916000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-476000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3392000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-179227000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1940000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-181167000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-181167000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-181167000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46200000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.92
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,46200000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.92
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,46195000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q2,2017-04-01,2017-06-30,2017-08-02 06:36:17+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.92
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,61220000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,46000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,61266000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,17436000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,17436000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,43830000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9972000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,2525000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10133000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22630000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,21200000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2956000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,10000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-683000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3629000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,17571000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7204000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,10367000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,10367000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,10367000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46344000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.22
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,65083000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.19
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,47100000.0
Sucampo Pharmaceuticals Inc,SCMP,549300YPLK5FSJFMAH24,0001365216,2017.0,Q3,2017-07-01,2017-09-30,2017-11-01 06:35:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.22
